RCS - Redx Pharma plc - Redx to Present at Wnt & ß-Catenin Pathway Summit

Redx PharmaAnnouncement

23/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230123:nRSW4718Na&default-theme=true

RNS Number : 4718N  Redx Pharma plc  23 January 2023

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present at the 2(nd) Annual Wnt & β-Catenin Pathway Targeted Drug
Development Summit

 

Alderley Park, UK, 23 January 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, announces that Dr. Simon Woodcock, Vice President, Oncology
at Redx Pharma, will present at the 2(nd) Annual Wnt & β-Catenin Pathway
Targeted Drug Development Summit (24 - 26 January, Boston, MA).

 

In the presentation, which will take place on Thursday 26 January at 10:30
(EST), Dr. Woodcock will discuss the challenges of genetic selection in
defined patient populations and how this relates directly to Wnt/β-Catenin
Biomarkers in patient selection for clinical studies of targeted therapies,
such as Redx's RXC004.

 

RXC004 is a clinical stage, highly potent and selective, orally active
Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand
dependent cancer. It is currently being evaluated in Phase 2 proof-of-concept
clinical studies as a monotherapy and in combination with anti-PD-1,
Nivolumab, in genetically selected metastatic colorectal cancer (MSS mCRC)
(clinicaltrials.gov (http://clinicaltrials.gov/)  NCT04907539), as
monotherapy in genetically selected pancreatic cancer, and as a monotherapy
and in combination with anti-PD-1, Pembrolizumab, in biliary tract cancers
(clinicaltrials.gov (http://clinicaltrials.gov/)  NCT04907851).

 

Details of the presentation are as follows:

 

 Title:      Leveraging Wnt/β-Catenin Biomarkers for Patient Selection for Targeted &
             Precision Therapies

 Day/Date:   Thursday, 26 January 2023

 Time:       10:30 EST

 

A copy of the presentation will be made available on the Company's website
following the presentation at:
https://www.redxpharma.com/scientific-publications/
(https://www.redxpharma.com/scientific-publications/)

 

 For further information, please contact:

 Redx Pharma Plc                                                       T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                           T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                        T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                            T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                        T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

T: +44 (0)203 705 9330

Panmure Gordon (UK) Limited (Joint Broker)

T: +44 (0)207 886 2500

Rupert Dearden/ Freddy Crossley/ Emma Earl

FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, being developed as
a targeted treatment for Wnt-ligand dependent cancers, commenced a Phase 2
programme in November 2021. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF)
in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing
towards a CTA/IND application at the end of 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor
targeting fibrotic diseases including IPF, which AstraZeneca is progressing in
a Phase 1 clinical study. In addition, Redx has forged collaborations with
Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by
Redx which Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFDLLIFFIV